{"id":"NCT01975246","sponsor":"Boehringer Ingelheim","briefTitle":"Add-on to Micamlo BP Trial","officialTitle":"An Eight-week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80 mg and Amlodipine 5 mg and Hydrochlorothiazide 12.5 mg vs. Telmisartan 80 mg and Amlodipine 5 mg in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Telmisartan 80 mg and Amlodipine 5 mg","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-11","primaryCompletion":"2014-06","completion":"2014-07","firstPosted":"2013-11-04","resultsPosted":"2016-11-29","lastUpdate":"2016-11-29"},"enrollment":309,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Hypertension"],"interventions":[{"type":"DRUG","name":"Telmisartan + amlodipine","otherNames":[]},{"type":"DRUG","name":"hydrochlorothiazide","otherNames":[]},{"type":"DRUG","name":"Telmisartan + amlodipine","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Telmisartan+amlodipine+HCTZ","type":"EXPERIMENTAL"},{"label":"Telmisartan+amlodipine","type":"ACTIVE_COMPARATOR"}],"summary":"This is a multi-centre, randomised, double-blind, active-controlled, parallel-group comparative trial to compare the fixed dose combination (FDC) of telmisartan 80 mg +hydrochlorothiazide 12.5 mg and amlodipine 5 mg (T80/A5/H12.5 mg) to telmisartan 80 mg+ amlodipine 5 mg (T80/A5 mg) in blood pressure lowering effect at week 8, the end of the double-blind period in essential hypertensive patients who fail to respond adequately to telmisartan 80 mg+ amlodipine 5 mg. Patients are assigned to one of the two groups after a 6-week open-label run-in period taking T80/A5 mg.","primaryOutcome":{"measure":"Change From Baseline in Mean Seated DBP at Trough After 8 Weeks of the Double-blind Period.","timeFrame":"baseline and week 8","effectByArm":[{"arm":"Telmisartan and Amlodipine+HCTZ","deltaMin":-8.4,"sd":0.5},{"arm":"Telmisartan+Amlodipine","deltaMin":-4.5,"sd":0.5}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":8},"locations":{"siteCount":30,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":149},"commonTop":["Blood uric acid increased","Nasopharyngitis","Hyperuricaemia"]}}